Sterling Capital Management’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.87K Sell
30
-23
-43% -$2.1K ﹤0.01% 2888
2026
Q1
$5.1K Sell
53
-3
-5% -$300 ﹤0.01% 2722
2025
Q4
$5.45K Buy
56
+36
+180% +$3.09K ﹤0.01% 2867
2025
Q3
$1.42K Buy
20
+1
+5% +$67 ﹤0.01% 3028
2025
Q2
$1.14K Buy
19
+10
+111% +$548 ﹤0.01% 3040
2025
Q1
$472 Hold
9
﹤0.01% 2966
2024
Q4
$495 Buy
9
+2
+29% +$105 ﹤0.01% 3037
2024
Q3
$352 Buy
+7
New +$323 ﹤0.01% 2992

Other funds holding IRMD

Sterling Capital Management's IRMD Position: Q2 2026 in Review

Sterling Capital Management reduced its iRadimed (IRMD) stake by 43% in Q2 2026, selling an estimated $2.1K and leaving 30 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

Sterling Capital Management first reported a position in IRMD in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.45K in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Sterling Capital Management held 30 shares of iRadimed worth $2.87K as of Q2 2026.
  • Sterling Capital Management sold 23 iRadimed shares in Q2 2026, an estimated $2.1K.
  • iRadimed made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2888 holding.
  • Sterling Capital Management first reported a position in iRadimed in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's iRadimed position peaked at $5.45K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.